federal food and drug administration fda expected announce soon will require additional review genentech inc tpa heart drug move likely will delay company plans market drug this spring government and wall street sources said tpa engineered blood clot dissolving drug which genentech hopes market under name activase will reviewed fda cardiorenal advisory committee during panel may meeting sources said neither genentech nor fda would confirm second review drug had been set under consideration for may meeting fda official said draft agenda similarly genentech spokeswoman said fda had not yet notified second advisory committee review possibility but this minute can confirm agenda said spokeswoman said second review had always been possibility but declined how review would marketing plans before receiving official fda spokeswoman acknowledged rumors second fda committee review had buffeted genentech stock yesterday wall street stock fell dlrs share clsoe dlrs tpa stands for tissue plasminogen activator and would used heart attack victims clear blockage vein artery blood clot dissolvers market tpa said more effective and with fewer side effects analysts have projected worldwide market for drug high billion dlrs year stuart weisbrod biotechnology analyst with prudential bache securities inc told reuters additional fda review likely would tpa off market until least november approval had been expected this spring said fda action prompted him cut his estimate genentech 1987 earnings about cents share from his earlier projection cents share said delay would lower genentech 1987 revenues from tpa about five six mln dlrs compared earlier projection mln dlrs 1987 revenues reuter 